Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BiomicaLabs
Munich, Bavaria, Germanyfutrue.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BiomicaLabs is a Munich-based biotechnology company and a subsidiary of the FUTRUE group, specializing in the development of artificial microbiomes for the treatment of serious diseases. The company's core technology, Mikro7, is a laboratory-engineered microbiome designed to restore health by fundamentally addressing microbiome-related pathologies. Founded by Dr. Clemens Fischer, BiomicaLabs aims to revolutionize the field of microbial therapy through the targeted transfer of these artificial consortia. The company is currently in the pre-clinical stage, with plans to initiate clinical trials in 2025.
- Therapeutic areas
- Other
- Modalities
- Artificial microbiomeMicrobial therapyLive biotherapeutic product therapy
- Industry
- Biotech
Beyond the preview
Go deeper on BiomicaLabs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BiomicaLabs.